Robert brings 25 years of life science capital market and corporate counsel experience.He founded the Company, and has served as Chairman and Chief Executive. Prior to Aurora, Robert founded and served as Chief Executive Officer of Medvax Technologies, a clinical stage cancer immunotherapy company developing dendritic cell and peptide cancer vaccines. Robert has been corporate counsel to numerous life science companies. He has participated in over $500 million of private and public offerings of life science and growth companies in the capital markets. He received his B.S. in Biology (pre-medicine concentration) Cum Laude from the University of Massachusetts, and Juris Doctorate from the University of Miami Law School. He has held a Series 7 securities license.
was one of the founders of VGX Pharmaceuticals, headed the corporate development merger with Inovio Pharmaceuticals (AMEX: INO) in 2009. He also headed series of funding resulted in more than $20M for Phase I and II clinical trials for 4 pipelines inc. DNA-vaccines in US. He was a co-founder/CEO at VGX International, a KOSPI public biotech company in Korea. He orchestrated acquisition of Dong-Il Fabric and initiated a new drug development division within the company in 2005. The company was selected as KOSPI 200 in 2008. As a global leader in DNA vaccine, the company successfully completed the first-ever preventive DNA vaccine phase 1 clinical trials in Asia. He led series of public funding in a total of $38M and structured numerous business deals including in-/out-licensing of pipelines with US and Chinese companies. He was named Forbes Korea’s CEO of the year in 2010 and Fortunes Korea’s Best CEOs in 2011.Prior to joining the company, he was a clinical associate professor at University of Pennsylvania. He holds a Doctor of Dental Medicine from University of Pennsylvania School of Dental Medicine, a BA in Economics and a BS in Biological Sciences from University of California at Irvine.